RESEARCH TRIANGLE PARK, N.C., June 6, 2011 /PRNewswire/ —
(NASDAQ: GRFS). Grifols, a global healthcare company and
biopharmaceutical manufacturer based in Barcelona, Spain, today
announced the establishment of a new Board of Directors for its
U.S. operations, including the appointment of Thomas Glanzmann as
Chairman of the Board, who previously was president of another
leading global plasma therapeutics business, and the reappointment
of Gregory Rich as Chief Executive Officer (CEO) of Grifols U.S.
operations.
(Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO)
Thomas Glanzmann was also appointed to direct the integration
process because of his past leadership experience in the plasma
industry and his history of successfully integrating other
companies with plasma product portfolios.
“It is an honor to serve in this capacity and with such an
experienced group of professionals,” said Thomas Glanzmann.
“I look forward to bringing together the outstanding
expertise of these two successful companies to create the world’s
leading plasma company,” Mr. Glanzmann said. With the transaction
now complete, Grifols will begin the process of integrating the two
companies.
Gregory Rich will continue as CEO of Grifols’ expanded U.S.
operations that now include manufacturing facilities and corporate
offices in North Carolina. “Our enlarged presence in the U.S.
will provide tremendous opportunities for us to expand patient
access to plasma therapies both domestically and around the world,”
stated Mr. Rich. “As we integrate our two companies into one,
our goal is to build on the exceptional customer service and
quality operations that people have come to expect from both
Grifols and Talecris,” said Mr. Rich. With more than thirty
years of experience in the plasma industry associated with Grifols,
Mr. Rich has driven Grifols’ profitability in the U.S., serving as
CEO of the US operations since 2003.
‘/>”/>
